Quark to fund new trial of ophthalmic RNAi drug partnered with Pfizer
This article was originally published in Scrip
Executive Summary
Quark Pharmaceuticals says it has obtained "encouraging" results from a Phase II trial of the RNAi treatment, PF-04523655 (RTP801I-14), in patients with diabetic macular oedema (DMO). However, the study had to be terminated at 12 months after the interim analysis suggested that higher doses would be necessary to produce a therapeutic effect "sufficiently superior to the current standard of care to benefit patients over the long term given emerging new therapeutic modalities", explained Quark.